US Stock Insider Trading | MapLight Therapeutics disclosed 4 insider transactions on February 24

K-LinePoet · 2026-03-07T04:14:57+00:00

MapLight Therapeutics disclosed multiple insider transactions on February 24, 2026. Director Malenka Robert C. sold a total of 10,800 shares on that day and the preceding days, involving nearly $198,400. The company focuses on improving the lives of patients with central nervous system diseases, with its main product ML-007C-MA aimed at treating schizophrenia and Alzheimer's disease.

K-LinePoet

2026-03-07 04:14:57

Abstract generation in progress

On February 24, 2026, MapLight Therapeutics (MPLT) disclosed four insider transactions. Director Malenka Robert C. sold 13,800 shares on February 24, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Director	Malenka Robert C.	February 24, 2026	Sell	736	18.15	$13,400
February 24, 2026	Director	Malenka Robert C.	February 23, 2026	Sell	476	19.06	$9,072.56
February 24, 2026	Director	Malenka Robert C.	February 20, 2026	Sell	2,195	18.03	$39,600
February 24, 2026	Director	Malenka Robert C.	February 23, 2026	Sell	10,800	18.39	$198,400
February 20, 2026	Director	Pavlov George	February 20, 2026	Buy	9,920	17.86	$178,200
February 20, 2026	Director	Pavlov George	February 18, 2026	Buy	10,700	17.48	$186,836
February 20, 2026	Director	Pavlov George	February 19, 2026	Buy	4,422	17.57	$77,700
February 18, 2026	Director	Malenka Robert C.	February 13, 2026	Sell	12,100	18.21	$220,000
February 12, 2026	Director	Malenka Robert C.	February 11, 2026	Sell	241	18.00	$4,338
February 12, 2026	Director	Garnett Timothy John	February 10, 2026	Buy	14,100	17.89	$252,700

【Company Profile】

MapLight Therapeutics, Inc. was incorporated in November 2018 under Delaware law. The company is a clinical-stage biopharmaceutical company focused on improving the lives of patients with neurodegenerative central nervous system (CNS) diseases. The company aims to address the lack of targeted drug therapies for specific neural circuits. Its discovery platform is designed to identify causal neural circuits related to disease and develop therapeutic modulation of these circuits. Its lead candidate, ML-007C-MA, is a fixed-dose combination intended to treat psychosis caused by schizophrenia and Alzheimer’s disease, aiming to activate specific muscarinic receptors in the central nervous system while minimizing peripheral side effects.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.